T1	Participants 56 100	microdose flare-up cycles in poor responders
T2	Participants 206 295	microdose gonadotropin-releasing hormone analog (GnRH-a) flare cycles in poor responders.
T3	Participants 382 400	total of 119 women
T4	Participants 587 599	119 patients
